• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Sarepta Therapeutics Set to Join S&P MidCap 400

    5/29/24 5:48:00 PM ET
    $JNJ
    $SPGI
    $SRPT
    $SWAV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Finance: Consumer Services
    Finance
    Get the next $JNJ alert in real time by email

    NEW YORK, May 29, 2024 /PRNewswire/ -- Sarepta Therapeutics Inc. (NASD: SRPT) will replace Shockwave Medical Inc. (NASD: SWAV) in the S&P MidCap 400 effective prior to the opening of trading on Monday, June 3. S&P 500 constituent Johnson & Johnson (NYSE:JNJ) is acquiring Shockwave Medical in a deal expected to be completed soon pending final closing conditions.

    Following is a summary of the changes that will take place prior to the open of trading on the effective date:

    Effective Date

    Index Name      

    Action

    Company Name

    Ticker

    GICS Sector

    June 3, 2024

    S&P MidCap 400

    Addition

    Sarepta Therapeutics

    SRPT

    Health Care

    June 3, 2024

    S&P MidCap 400

    Deletion

    Shockwave Medical

    SWAV

    Health Care

    For more information about S&P Dow Jones Indices, please visit www.spdji.com

    ABOUT S&P DOW JONES INDICES

    S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets.

    S&P Dow Jones Indices is a division of S&P Global (NYSE:SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spdji.com.

    FOR MORE INFORMATION:

    S&P Dow Jones Indices

    [email protected]

    Media Inquiries

    [email protected]

    Cision View original content:https://www.prnewswire.com/news-releases/sarepta-therapeutics-set-to-join-sp-midcap-400-302158643.html

    SOURCE S&P Dow Jones Indices

    Get the next $JNJ alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $JNJ
    $SPGI
    $SRPT
    $SWAV

    CompanyDatePrice TargetRatingAnalyst
    Johnson & Johnson
    $JNJ
    11/13/2025$230.00Sector Outperform
    Scotiabank
    Sarepta Therapeutics Inc.
    $SRPT
    11/5/2025$26.00Neutral → Outperform
    Mizuho
    Johnson & Johnson
    $JNJ
    10/20/2025$203.00Neutral → Outperform
    Daiwa Securities
    Johnson & Johnson
    $JNJ
    10/3/2025$212.00Equal Weight → Overweight
    Wells Fargo
    S&P Global Inc.
    $SPGI
    10/1/2025$540.00Buy
    Seaport Research Partners
    Johnson & Johnson
    $JNJ
    9/23/2025$206.00Neutral → Buy
    Guggenheim
    Sarepta Therapeutics Inc.
    $SRPT
    9/22/2025$50.00Market Perform → Outperform
    BMO Capital Markets
    Sarepta Therapeutics Inc.
    $SRPT
    7/29/2025$22.00Underweight → Equal Weight
    Barclays
    More analyst ratings

    $JNJ
    $SPGI
    $SRPT
    $SWAV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President, R&D and Tech Ops Rodino-Klapac Louise covered exercise/tax liability with 4,582 shares, decreasing direct ownership by 2% to 224,030 units (SEC Form 4)

    4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)

    11/19/25 8:05:03 PM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Clay Catherine R

    3 - S&P Global Inc. (0000064040) (Issuer)

    11/4/25 4:06:26 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    Chief Communications Officer Twomey Christina exercised 188 shares at a strike of $487.21 and covered exercise/tax liability with 65 shares, increasing direct ownership by 17% to 831 units (SEC Form 4)

    4 - S&P Global Inc. (0000064040) (Issuer)

    11/4/25 4:01:50 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    $JNJ
    $SPGI
    $SRPT
    $SWAV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    S&P Global Launches WSO Compliance Insights to Streamline Credit Risk Management

    Compliance solution available through S&P Global Market Intelligence addresses the growing need for private credit and CLO managers to report on increasingly complex loan portfoliosReal-time data streaming facilitates accuracy and timeliness for compliance testsHypothetical trade management supports cross-deal, cross-asset allocation and shell asset creationNEW YORK, Nov. 20, 2025 /PRNewswire/ -- S&P Global (NYSE:SPGI) today announced the launch of WSO Compliance Insights, a comprehensive compliance management solution designed to enhance credit risk management for private credit and CLO managers. This application, available through S&P Global Market Intelligence, utilizes real-time data str

    11/20/25 4:01:00 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    Bidgely CEO Abhay Gupta Named Chief Trailblazer of the Year Finalist for 2025 S&P Platts Global Energy Awards

    Gupta recognized for visionary leadership, innovative AI solutions driving energy resilience Abhay Gupta, the pioneering founder and CEO of Bidgely, has been named a finalist for Chief Trailblazer of the Year in the 27th Annual Platts Global Energy Awards. This distinguished honor recognizes Gupta's profound impact on the energy sector, driven by his groundbreaking approach to artificial intelligence (AI) and a relentless pursuit of a more resilient and stable energy future. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251119726431/en/Pioneering founder and CEO of Bidgely, Abhay Gupta, is a finalist for 27th Annual Platts Gl

    11/19/25 4:12:00 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    CARFAX: Nearly Half of Drivers in the U.S. Behind on Major Services

    Drivers Should Make Sure Vehicles Are Ready for Holiday Travel CENTREVILLE, Va., Nov. 18, 2025 As millions of people hit the road for the holidays, CARFAX has found that nearly half of all drivers are behind on at least one major service. CARFAX data found that roughly 41% of vehicles nationwide are overdue for some critical maintenance work. According to CARFAX, these "major services" include: BRAKES: Brake line and rotor inspections and replacementsSTEERING: Vehicle suspension and steering components inspectionDRIVETRAIN: Transmission fluid draining and refillingENGINE: Cool

    11/18/25 9:01:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    $JNJ
    $SPGI
    $SRPT
    $SWAV
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for AMONDYS 45 issued to SAREPTA THERAPS INC

    Submission status for SAREPTA THERAPS INC's drug AMONDYS 45 (SUPPL-8) with active ingredient CASIMERSEN has changed to 'Approval' on 07/11/2024. Application Category: NDA, Application Number: 213026, Application Classification: Labeling

    7/12/24 4:40:36 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    June 20, 2024 - FDA Expands Approval of Gene Therapy for Patients with Duchenne Muscular Dystrophy

    For Immediate Release: June 20, 2024 Today, the U.S. Food and Drug Administration expanded the approval of Elevidys (delandistrogene moxeparvovec-rokl), a gene therapy for the treatment of Duchenne muscular dystrophy (DMD) for ambulatory and non-ambulatory individuals 4 years of age and older with DMD with a confirmed mutation in the DMD gene.  Elevidys was previously approved under accelerated approval for amb

    6/20/24 5:24:42 PM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for VYONDYS 53 issued to SAREPTA THERAPS INC

    Submission status for SAREPTA THERAPS INC's drug VYONDYS 53 (SUPPL-11) with active ingredient GOLODIRSEN has changed to 'Approval' on 06/04/2024. Application Category: NDA, Application Number: 211970, Application Classification: Labeling

    6/5/24 4:41:31 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $SPGI
    $SRPT
    $SWAV
    SEC Filings

    View All

    SEC Form 13F-HR filed by Johnson & Johnson

    13F-HR - JOHNSON & JOHNSON (0000200406) (Filer)

    11/13/25 3:25:42 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    S&P Global Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - S&P Global Inc. (0000064040) (Filer)

    11/13/25 7:55:11 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    S&P Global Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - S&P Global Inc. (0000064040) (Filer)

    11/10/25 9:00:13 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    $JNJ
    $SPGI
    $SRPT
    $SWAV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Scotiabank initiated coverage on Johnson & Johnson with a new price target

    Scotiabank initiated coverage of Johnson & Johnson with a rating of Sector Outperform and set a new price target of $230.00

    11/13/25 9:14:21 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sarepta Therapeutics upgraded by Mizuho with a new price target

    Mizuho upgraded Sarepta Therapeutics from Neutral to Outperform and set a new price target of $26.00

    11/5/25 7:25:02 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson & Johnson upgraded by Daiwa Securities with a new price target

    Daiwa Securities upgraded Johnson & Johnson from Neutral to Outperform and set a new price target of $203.00

    10/20/25 8:00:27 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $SPGI
    $SRPT
    $SWAV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Weinberger Mark A bought $147,220 worth of shares (1,000 units at $147.22) (SEC Form 4)

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    12/12/24 5:27:36 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Chambers Michael Andrew bought $4,955,728 worth of shares (37,038 units at $133.80) (SEC Form 4)

    4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)

    8/20/24 8:00:04 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Jacoby Rebecca bought $8,971 worth of shares (69 units at $130.01), increasing direct ownership by 17% to 469 units (SEC Form 4)

    4 - S&P Global Inc. (0000064040) (Issuer)

    6/17/24 4:04:40 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    $JNJ
    $SPGI
    $SRPT
    $SWAV
    Leadership Updates

    Live Leadership Updates

    View All

    Sterling Infrastructure Set to Join S&P MidCap 400 and Red Rock Resorts to Join S&P SmallCap 600

    NEW YORK, Nov. 6, 2025 /PRNewswire/ -- Sterling Infrastructure Inc. (NASD: STRL) will replace Light & Wonder Inc. (NASD: LNW) in the S&P MidCap 400, and Red Rock Resorts Inc. (NASD: RRR) will replace Sterling Infrastructure in the S&P SmallCap 600 effective prior to the opening of trading on Thursday, November 13. Light & Wonder is expected to delist from the NASDAQ Stock Exchange on or around that date and intends to keep its primary listing exclusively in Australia. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector Nov 13, 2025 S&P MidCap 400 Addition Sterli

    11/6/25 6:20:00 PM ET
    $LNW
    $RRR
    $SPGI
    EDP Services
    Technology
    Hotels/Resorts
    Consumer Discretionary

    Solstice Advance Materials and Qnity Electronics Set to Join S&P 500; Others to Join S&P SmallCap 600

    NEW YORK, Oct. 27, 2025 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P SmallCap 600: Solstice Advance Materials Inc. (NASD: SOLS) will replace CarMax Inc. (NYSE:KMX) in the S&P 500, and CarMax will replace USANA Health Sciences Inc. (NYSE:USNA) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, October 31. S&P 500 and 100 constituent Honeywell International Inc. (NASD: HON) is spinning off Solstice Advance Materials in a transaction expected to be completed on October 30. Post spin-off, Honeywell International will remain in the S&P 500 and 100. CarMax and USANA Health Sciences no longer represent the large cap and small c

    10/27/25 6:10:00 PM ET
    $CAL
    $DD
    $EMN
    Shoe Manufacturing
    Consumer Discretionary
    Major Chemicals
    Industrials

    BrightSpring Health Services Set to Join S&P SmallCap 600

    NEW YORK, Oct. 14, 2025 /PRNewswire/ -- BrightSpring Health Services Inc. (NASD: BTSG) will replace Veritex Holdings Inc. (NASD: VBTX) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, October 20. S&P 500 constituent Huntington Bancshares Inc. (NASD: HBAN) is acquiring Veritex Holdings in a deal expected to close soon, pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector October 20, 2025 S&P SmallCap 600 Addition BrightSpring Health Services BTSG Health Care October 20, 2025 S&P SmallCap 600 Deletion Veritex H

    10/14/25 6:00:00 PM ET
    $BTSG
    $HBAN
    $SPGI
    Medical/Nursing Services
    Health Care
    Major Banks
    Finance

    $JNJ
    $SPGI
    $SRPT
    $SWAV
    Financials

    Live finance-specific insights

    View All

    S&P Global to Present Next Phase of its Growth Strategy and Medium-Term Financial Targets at Investor Day 2025

    Company to Outline its Mission of Advancing Essential Intelligence  Announces New Share Repurchase Program, up to 30 Million Shares NEW YORK, Nov. 13, 2025 /PRNewswire/ -- S&P Global (NYSE: SPGI) will present the next phase of its growth strategy at its 2025 Investor Day today in New York. S&P Global President and Chief Executive Officer Martina Cheung and executives will discuss how S&P Global is "advancing essential intelligence" to enable its customers to make more confident decisions and remain a step ahead with S&P Global's industry-leading solutions. S&P Global (NYSE:SP

    11/13/25 8:00:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    Sarepta Therapeutics Announces Third Quarter 2025 Financial Results and Recent Corporate Developments, Including Completion of Its Confirmatory Study, ESSENCE

    Sarepta announces completion of the confirmatory trial commitment for its ultra-rare disease PMO therapies AMONDYS 45 and VYONDYS 53: While the ESSENCE study did not achieve statistical significance on its primary endpoint, results indicate positive and encouraging trends favoring therapy at 96 weeks Sarepta reports that the study was impacted by the COVID-19 pandemic and, when COVID-impacted data is excluded, meaningful treatment effect is seen on the primary endpoint ESSENCE supported favorable safety profile of AMONDYS 45 and VYONDYS 53 The Company intends to schedule a meeting with FDA to discuss path to a traditional approval based on the positive risk-benefits of the thera

    11/3/25 4:05:00 PM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    S&P Global Reports Third Quarter Results

    NEW YORK, Oct. 30, 2025 /PRNewswire/ -- S&P Global (NYSE:SPGI) today reported third quarter results. The Company's earnings release and supplemental materials are available at http://investor.spglobal.com/Quarterly-Earnings.  Supplemental Information/Conference Call/Webcast Details: The Company's senior management will review the third quarter 2025 earnings results on a conference call scheduled for today, October 30, at 8:30 a.m. EDT. Additional information presented on the conference call, and the Company's supplemental slide content may be found on the Company's Investor Re

    10/30/25 7:18:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    $JNJ
    $SPGI
    $SRPT
    $SWAV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sarepta Therapeutics Inc.

    SC 13G/A - Sarepta Therapeutics, Inc. (0000873303) (Subject)

    11/13/24 10:27:59 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Johnson & Johnson

    SC 13G - JOHNSON & JOHNSON (0000200406) (Filed by)

    4/10/24 5:12:55 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by ShockWave Medical Inc. (Amendment)

    SC 13G/A - Shockwave Medical, Inc. (0001642545) (Subject)

    2/13/24 5:13:59 PM ET
    $SWAV
    Medical/Dental Instruments
    Health Care